Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 883-896, October 2008

Epstein–Barr virus in autoimmune diseases

  • Éric Toussirot, MD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author: Tel.: +33 3 81 66 82 41; Fax: +33 3 81 66 86 86.

Department of Rheumatology, University Hospital Jean Minjoz, Besançon; and EA 3186 Agents Pathogènes et Inflammation, University of Franche Comté, Besançon, France

INSERM U639, Université de la Méditerranée, Marseille; and Rheumatology Department, La Conception Teaching Hospital, APHM Marseille, France

Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and primary Sjögren's syndrome (pSS) are complex disorders with a genetic background and the involvement of environmental factors, including viruses. The Epstein–Barr virus (EBV) is a plausible candidate for playing a role in the pathophysiology of these diseases. Both SLE and RA are characterized by high titers of anti-EBV antibodies and impaired T-cell responses to EBV antigens. Compared with normal subjects, elevated EBV load in peripheral blood has been observed in SLE and RA. EBV DNA or RNA has been evidenced in target organs of RA (synovium) or pSS (salivary glands). Finally, molecular mimicry has been demonstrated between EBV proteins and self antigens in these three conditions. In addition, SLE, RA, and pSS are associated with an increased risk of lymphoma with a potential role for EBV. The influence of new and emergent treatments of these autoimmune diseases (biological therapies) on EBV load and the course of latent EBV infection requires further studies.

Key words: autoimmune diseases, Epstein–Barr virus, molecular mimicry

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(08)00104-6

doi:10.1016/j.berh.2008.09.007

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 883-896, October 2008